Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486)

Abstract

These encouraging results strongly support a prospective clinical trial in this preselected population.

Hormone-dependent shrinkage of a sphenoid wing meningioma after pregnancy: case report

“…A re cent publication showed favorable results in postmeno pausal patients with multiple meningiomas with up to 10 years of followup. 27 Overall, the side effects of longterm RU486 treatment seem to be minor, so no discontinua tion of treatment was necessary in either study. Immuno histochemical progesterone receptor staining was done, although there was no proof of progesterone receptor expression; such staining seems to be mandatory when considering RU486 treatment.…”

Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence

“…Although tumour recurrence is an important and not infrequent event, our knowledge on predisposing factors is rather limited. The risk of recurrence increases with the WHO grade being 7-25% in WHO grade I, 30-50% in WHO grade II and 50-95% in WHO grade III [27,28,32,33]. The extent of resection assessed by the Simpson Grading System influences recurrence rates which is one reason of the wide range of probability [30].…”

Meningiomas’ Management: An Update of the Literature

“…Clinical studies on its efficacy show, however, contrasting results [7,76,77], and only minor evidences exist to recommend mifepristone with inoperable progressive meningiomas, after consideration of the histological grade of the tumor and progesterone receptor expression [78]. Positive preliminary results were obtained with diffuse meningiomatosis [79].…”